Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795548 | 0.85 | MAPT (0.45) | LMNAMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18795981 | 0.84 | MAPT (0.44) | LMNAMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18795791 | 0.84 | MAPT (0.47) | LMNAMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18795625 | 0.83 | TP53 (0.43) | LMNAMAPTHTTMRGPRX4ALDH1A1 | |
| SCHEMBL18795641 | 0.83 | MAPT (0.44) | LMNAMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL19206908 | 0.83 | LMNA (0.39) | LMNAMAPTHTTMRGPRX4ALDH1A1 | |
| SCHEMBL18795945 | 0.83 | MAPT (0.42) | LMNAMAPTHTTMRGPRX4ALDH1A1 | |
| SCHEMBL18795704 | 0.82 | CFTR (0.47) | LMNAMAPTHTTMRGPRX4ALDH1A1 | |
| SCHEMBL18795490 | 0.80 | MAPT (0.47) | LMNAMAPTHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18795205 | 0.80 | CFTR (0.47) | LMNAMAPTHTTMRGPRX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-110366556-B | Antibacterial peptide macrocyclic compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3609904-B1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-11-30 | — | — | EP | disclosed |
| US-11066443-B2 | Anti-bacterial peptide macrocycles and use thereof | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| EP-3609904-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-20200040031-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | HOFFMANN LA ROCHE (US) | 2020-02-06 | — | — | US | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| WO-2018189065-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388444-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066443-B2 | Anti-bacterial peptide macrocycles and use thereof | CFTR, VIP, NGLY1 | LMNA 3511/4885MAPT 4718/4885HTT 2536/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | LMNA 3944/4885MAPT 4627/4885HTT 4717/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | LMNA 3944/4885MAPT 4627/4885HTT 4717/4885 |
| US-20200040031-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | CFTR, VIP, NGLY1 | LMNA 3511/4885MAPT 4718/4885HTT 2536/4885 |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | LMNA 3944/4885MAPT 4627/4885HTT 4717/4885 |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | LMNA 3944/4885MAPT 4627/4885HTT 4717/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | LMNA 3944/4885MAPT 4627/4885HTT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.